Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909227 | 0.87 | SLC22A12 (0.47) | PLAUCTSAKDM5AKDM5BSLC22A12 | |
| SCHEMBL9907366 | 0.84 | KMO (0.44) | PLAUALOX15HTT | |
| SCHEMBL9909306 | 0.81 | HTR5A (0.51) | PLAU | |
| SCHEMBL9907429 | 0.81 | ALOX15 (0.37) | CYP11B1CYP11B2IDH1SCN9AALOX15 | |
| SCHEMBL9909154 | 0.79 | F10 (0.48) | CYP11B1CYP11B2SCN9AALOX15HTT | |
| SCHEMBL9909212 | 0.79 | NR1H4 (0.40) | PLAUSCN9AALOX15HTT | |
| SCHEMBL9925448 | 0.76 | HTR5A (0.52) | CYP11B1CYP11B2CTSAEGLN1MRGPRX4 | |
| SCHEMBL9909251 | 0.76 | CYP11B1 (0.39) | CYP11B1CYP11B2SLC22A12EGLN1MRGPRX4 | |
| SCHEMBL9100686 | 0.76 | HTT (0.44) | CYP11B1CYP11B2KDM5AKDM5BALOX15 | |
| SCHEMBL12875031 | 0.76 | ALOX15 (0.45) | CYP11B1CYP11B2SCN9AALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | CYP11B1 1230/4885CYP11B2 1061/4885IDH1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.